EGFR-targeted drugs have significantly improved the therapeutic efficacy of NSCLC due to their high selectivity and low side effects (Garcia-Campelo et al., 2020; Kim et al., 2019; Remon et al., 2018). This evidence concerns the gene EGFR and non-small cell lung carcinoma.